Veru (NASDAQ:VERU) Upgraded by Wall Street Zen to Hold Rating

Veru (NASDAQ:VERU) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other research analysts also recently commented on the stock. Canaccord Genuity Group began coverage on shares of Veru in a research note on Thursday. They issued a “buy” rating and a $25.00 target price on the stock. Oppenheimer reissued an “outperform” rating on shares of Veru in a report on Thursday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Veru in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Veru Trading Up 2.7%

NASDAQ VERU opened at $2.32 on Friday. The firm has a market cap of $37.24 million, a PE ratio of -1.05 and a beta of -1.01. Veru has a 1-year low of $2.11 and a 1-year high of $14.20. The stock has a 50-day moving average of $2.89 and a 200-day moving average of $4.09.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in VERU. MPM Bioimpact LLC boosted its stake in shares of Veru by 53.8% during the 1st quarter. MPM Bioimpact LLC now owns 6,592,727 shares of the company’s stock valued at $3,231,000 after purchasing an additional 2,307,362 shares in the last quarter. Marshall Wace LLP purchased a new stake in Veru in the second quarter worth about $220,000. Sheets Smith Investment Management boosted its position in Veru by 1,341.9% during the 3rd quarter. Sheets Smith Investment Management now owns 322,084 shares of the company’s stock valued at $1,224,000 after acquiring an additional 299,746 shares in the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Veru during the 2nd quarter worth approximately $152,000. Finally, Nuveen LLC bought a new position in shares of Veru in the 1st quarter worth approximately $88,000. 47.16% of the stock is currently owned by institutional investors.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.